Premium
Clinical safety surveillance study of the safety and efficacy of long‐term home treatment with ReFacto ® utilizing a computer‐aided diary: a Nordic multicentre study
Author(s) -
PETRINI P.,
RYLANDER C.
Publication year - 2009
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2008.01863.x
Subject(s) - medicine , pediatrics , haemophilia , patient safety , emergency medicine , surgery , health care , economics , economic growth
Summary. A Nordic multicentre, open‐label, non‐interventional postmarketing surveillance study was carried out during a period of 24 months evaluating safety and efficacy of ReFacto as prophylactic or on‐demand replacement therapy in patients with haemophilia A treated by self‐medication. Fifty‐seven patients were enrolled and studied for safety; efficacy was evaluated in 39 patients who received ReFacto for 24 months and recorded sufficient diary data on a hand‐held computer. The compliance of using the device was good in small children, variable in adults and poor in teenagers. The fact that the overall compliance was low constituted a limitation of the number of patients with reliable diary data. Overall safety was rated as excellent or good by the clinicians for all patients at all visits and overall efficacy at 24 months evaluated to be excellent (74%) or good (26%). It was noticed that ≥50% of patients/parents reported no absences from school or work owing to bleeding episodes during the study period. Among patients on regular prophylaxis, 6 of the 30 patients (20%) receiving ReFacto experienced no bleeding episodes. A median of four bleeding episodes occurred during the 24‐month study period, and 93% of the episodes were resolved with ≤2 ReFacto infusions. In the 7 on‐demand patients, there was a median of 18 bleeding episodes, 87% of which resolved with ≤2 ReFacto infusions. Interestingly, 42% of the ReFacto infusions taken by the patients classified to the on‐demand group were registered as prophylactic treatment. In conclusion, ReFacto demonstrated good safety and efficacy in prophylaxis as well as treatment of bleeding episodes.